US 12,240,880 B2
De novo design of potent and selective interleukin mimetics
Daniel Adriano Silva Manzano, Seattle, WA (US); Shawn Yu, Seattle, WA (US); Umut Ulge, Seattle, WA (US); David Baker, Seattle, WA (US); Kenan Christopher Garcia, Stanford, CA (US); Jamie Spangler, Stanford, CA (US); and Carl Walkey, Seattle, WA (US)
Assigned to UNIVERSITY OF WASHINGTON, Seattle, WA (US); and THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, Stanford, CA (US)
Filed by UNIVERSITY OF WASHINGTON, Seattle, WA (US); and THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, Stanford, CA (US)
Filed on Mar. 18, 2022, as Appl. No. 17/698,553.
Application 17/698,553 is a division of application No. 16/909,210, filed on Jun. 23, 2020, granted, now 11,401,313.
Application 16/909,210 is a division of application No. 16/572,038, filed on Sep. 16, 2019, granted, now 10,703,791, issued on Jul. 7, 2020.
Application 16/572,038 is a continuation of application No. PCT/US2019/038703, filed on Jun. 24, 2019.
Claims priority of provisional application 62/768,733, filed on Nov. 16, 2018.
Claims priority of provisional application 62/689,769, filed on Jun. 25, 2018.
Prior Publication US 2022/0235110 A1, Jul. 28, 2022
Int. Cl. C07K 14/55 (2006.01); A61K 38/00 (2006.01); A61K 47/60 (2017.01); A61K 47/62 (2017.01); C07K 14/54 (2006.01)
CPC C07K 14/55 (2013.01) [A61K 47/60 (2017.08); A61K 47/62 (2017.08); C07K 14/5406 (2013.01); C07K 14/5437 (2013.01); C07K 14/5443 (2013.01); A61K 38/00 (2013.01); C07B 2200/13 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C07K 2319/74 (2013.01)] 20 Claims
 
1. A method for treating cancer comprising administering to a subject having cancer a non-naturally occurring polypeptide comprising domains X1, X2, X3, and X4, wherein:
(a) X1 is a peptide comprising the amino acid sequence EHALYDAL (SEQ ID NO: 1);
(b) X2 is a helical-peptide of at least 8 amino acids in length;
(c) X3 is a peptide comprising the amino acid sequence YAFNFELI (SEQ ID NO:2);
(d) X4 is a peptide comprising the amino acid sequence ITILQSWIF (SEQ ID NO:3);
wherein X1, X2, X3, and X4 may be in any order in the polypeptide;
wherein amino acid linkers may be present between any of the domains; and
wherein the polypeptide binds to IL-2 receptor βcustom characterc heterodimer (IL-2Rβcustom characterc).